ABSTRACT. Dried blood spots are used for newborn screening because of ease of sample collection, handling, and shipment. DNA is stable and accessible in the filter paper matrix. Genotypic confirmation using initial specimens is demonstrated for a regional screening program. Seventy-five blinded samples underwent DNA analysis after Hb electrophoresis. DNA was microextracted from a %-inch semicircle (25 pL whole blood equivalent), amplified, and analyzed by four different methods. Direct amplification without microextraction and automated sequencing from microextracted DNA also was performed. All four analyses agreed for the A and S alleles in 70 of 75 specimens. Three disagreements were clarified by the other semicircle from the original sample: two were due to polymerase chain reaction contamination and one to contamination of one of four analytical tests. Two would have required analysis of a second specimen, one because of polymerase chain reaction failure and the second because the patient had SIB-thalassemia. Direct amplification without microextraction was successful in an additional 77 of 78 specimens for analysis of the A, S, C, and E alleles. Automated direct sequencing from microextracted DNA was demonstrated for the A, S, and C alleles. Analysis of microextracted DNA from dried blood specimens for A and S alleles reduced the need for and costs of obtaining a second specimen for confirmation by 97%. Direct amplification without microextraction for analysis of A, S, and C alleles permits additional reduction in personnel time and costs. We have demonstrated that microextracted DNA is amenable to automated sequencing after asymmetric polymerase chain reaction. Direct genotypic confirmation can facilitate diagnosis and initiation of medical intervention. (Pediatr Res 31: 217-221,1992) Abbreviations PCR, polymerase chain reaction PKU, phenylketonuria CF, cystic fibrosis ASO, allele specific oligonucleotide HRP, horseradish peroxidase
The collection of newborn screening specimens on filter paper blotters represented a major innovation that facilitated the establishment and regionalization of screening programs (1, 2) . These screening programs were originally developed for PKU, but are incorporating an expanding group of disorders, including the hemoglobinopathies (3) . With rare exceptions, these expanded test batteries have continued to use dried blood specimens in a filter paper matrix because of the ease of sample collection, handling, and shipment and the stability of the analytes. Typically, the analytes evaluated by neonatal screening laboratories have included metabolites such as phenylalanine for PKU, or galactose and galactose-1-phosphate for galactosemia; hormones such as thyroid hormone and thyroid stimulating hormone (TSH) for congenital hypothyroidism, or 17-hydroxyprogesterone for congenital adrenal hyperplasia; and proteins such as galactose-1-phosphate uridyl transferase for galactosemia, immunoreactive trypsinogen for CF, or Hb for the hemoglobinopathies (1, 3, 4).
More recently, it has become evident that DNA is also a stable and accessible analyte in dried blood specimens (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) . Because the individual's DNA is present in all nucleated cells, any mutations represented in an individual can be detected using the dried sample of peripheral blood without regard for tissue or developmental stage specific expression of the phenotype. This latter characteristic is valuable for a hemoglobinopathy screening program, because the adult Hb genes are submaximally expressed at birth and in the perinatal period. Direct genotyping from the original newborn blotter would permit early and rapid confirmation of positive screening tests, clarification of equivocal results, and effective initiation of penicillin prophylaxis to prevent mortality related to overwhelming infection in patients diagnosed with sickle cell disease (10, 22, 23) . Previous studies have demonstrated the possibility of DNA follow-up for hemoglobinopathy screening (10, 11) . In this report, we describe the results of a study evaluating the integration of direct genotypic confirmation with a regional, protein-based, neonatal screening laboratory. This study examines the validation of DNA analyses in this setting and the influence of the DNA confirmatory laboratory on requirements for repeat specimens. In addition, we provide results demonstrating the feasibility of improving the automation and cost-effectiveness of DNA follow-up.
Inc., Keene, NH) after all routine screening tests had been performed. The identity and electrophoretic results of these were unknown to all of the personnel in the DNA laboratory. The results from the state screening laboratory were revealed only after the DNA genotype had been determined. DNA microextraction. A '/z-inch semicircle was cut from each specimen circle of dried blood using stainless steel scissors that were routinely washed in 0.3 N HC1 for 10 min between samples to depurinate DNA and prevent cross-contamination of specimens (10) . Each semicircle represented the dried equivalent of approximately 25 pL of whole blood (5, 10, 24) . The microextraction procedure was similar to that reported previously (lo), with the exception that the proteinase K digestion was extended from 2 to approximately 16 h (overnight) to improve DNA yield. The procedure included methanol fixation, SDS and proteinase K treatment, phenol extraction (three times), chloroform-isopropyl alcohol extraction (two times), ethanol precipitation, and drying the precipitated DNA. After dissolving the DNA in 100 p L TE (10 mM Tris HC1 and 1 mM EDTA, pH 8.0), the quality was evaluated and the concentration was estimated by electrophoresis of a 10-pL aliquot with standards of known concentration on a 1% agarose (Sea Kem ME) gel that was stained with ethidium bromide. The DNA median yield was 1500 nglsemicircle (range 900-2000 ng/semicircle) or approximately 60 ng/ p L dried equivalent of whole blood (range 36-80 ng/pL).
Amplification. An aliquot of DNA (generally 200-300 ng or 10-20% of the microextracted material) was taken for amplification using 2.5 U Thermus aquaticus (Tag) polymerase (Cetus Corp., Emeryville, CA), and reaction buffer and other components as previously described (lo), for a reaction volume of 100 pL. A DNA Thermal Cycler (Perkin Elmer Cetus, Nonvalk, CT) was used for 30 cycles of amplification: denaturation 94°C for 0.5 min, annealing 55°C for 0.5 min, and extension 72°C for 1.0 min. Two primers flanking a 299-bp genomic region containing A reagent blank controlled for contamination of the assay components.
Products of the direct amplification reactions were analyzed for the A, S, C, and E alleles using dot-blot or slot-blot hybridizations with radiolabeled AS0 probes. The A, S, and C AS0 were 1 9-mers previously described (p 19A, p 19S, and p 19C) (27) , and the E AS0 was a 20-mer, which we have designated p20E (5'-AAGTTGGTGGTAAGGCCCTG-3').
Automated direct sequencing. Microextracted DNA was amplified using oligonucleotide primers flanking the mutation site (no. 203, 5'-GACACAACTGTGTTCACTAGCAACC-3'; no.
1 180,5'-ATCCTGAGACTTCCACACTGATGCA-3 '). Fluorescent DNA sequence primers were prepared and fluorescent DNA sequencing carried out according to Gibbs et al. (30) using the ABI Automated Sequencer (Applied Biosystems, Foster City, CA).
RESULTS
Each of the 75 specimens was amplified and analyzed by all four DNA methods. Figure 1 shows an example of the results obtained after hybridization of a slot blot with radiolabeled AS0 for the A and S alleles. Each group of unknowns was accompanied by known AA, AS, and SS DNA specimens ( Fig. 1 , lower portion). A typical dot-blot hybridization with HRP-labeled AS0 is shown in Figure 2 , with the controls in the lower right portion of each dot blot. After direct DdeI digestion of the PCR-amplified products, these were electrophoretically separated and stained with ethidium bromide as shown in Figure 3 (controls on the right). Southern blots of undigested PCR products were hybridized with radiolabeled AS0 probes identical to those used for the dot-or slot-blot hybridizations (results not shown).
When the results of the state laboratory Hb electrophoresis and the initial results from the DNA laboratory were compared, the sickle cell mutation were used k 0 3 (25)and PMClll6
(5'-CTCAAAGAACCTCTGGGTCC-3').
Amplification without microextraction. Although the method described above for microextraction and amplification was used pA Probe pS Probe for all of the original 75 blinded specimeni obtained from the Texas Newborn Screening Laboratory in Austin, subsequently we adapted a method from Schwartz et al. (26) and previous work on boiling of specimens from our group (10) that avoided the need for manual microextraction. Aliquots measuring approximately 4 x 4 mm (representing the dried equivalent of approximately 8 pL whole blood) were cut from each dried blood specimen and placed in 1.5-mL microfuge tubes to which the complete amplification cocktail including primers, and in some cases Tag polymerase, were added as described above. These microfuge tubes were then placed in the automated thermal cycler programmed with an initial 15-min step at 95°C followed by 30 cycles of amplification described above, modified to increase the 94°C denaturation step from 0.5 to 1.0 min. If Tag polymerase had not been added before the initial 15-min cycle, it was added after this step and before the 30-cycle amplification program was initiated. After amplification, the tubes were centrifuged and the supernatants were removed and aliquoted for analysis.
Analysis. Four detection methods were used to analyze the amplified products in the blinded assessment of samples from the state screening laboratory. Each method used 10-20 pL of the 100-pL PCR reaction volume. Two of these methods were based on dot or slot blot hybridizations of amplified DNA with AS0 probes (p 19A and p 19s) (27) , either labeled with radioactive phosphorus (32P) (10) or HRP (12, 25) . The third approach involved direct digestion of the PCR amplified products with DdeI and separation of the restriction fragments by agarose electrophoresis in a method adapted from Kazazian (28) . The fourth method used Southern blotting (29) and hybridization with 32P-labeled ASO. Routine controls included patients' samples of known genotypes AA, AS, and SS for the blinded study. there was complete agreement in 70 of the 75 specimens ( Table  1 ). The five samples that showed a disagreement were numbers 2,42,45,47, and 6 1. When samples 42,45, and 6 1 were repeated in the DNA laboratory using the original specimens, the results agreed with the state laboratory. For samples 42 and 45, the state laboratory results were FA and the original DNA laboratory results were AS by all four methods. When 42 and 45 were reextracted in the DNA laboratory, the results were AA on all four methods. This suggests that the initial results for 42 and 45 were due to contamination during the first DNA microextraction or the initial PCR amplification. It is interesting to note that 42 and 45 were in the same batch during their initial testing in the DNA laboratory. For sample 6 1, three of the original tests in the DNA laboratory showed SS in agreement with the state laboratory result of FS. The fourth DNA analysis on sample 61, using the dot blot HRP-coupled ASO, showed AS. Repeating the analysis on sample 6 1 using the remaining specimen showed FS for all four methods in the DNA laboratory. This suggested that the initial disagreement was due to contamination at the dotblot step after aliquoting the amplification products.
To resolve the disagreement for samples 2 and 47, we requested a repeat specimen from the state laboratory. The initial testing of sample 47 gave inadequate amplification of the microextracted DNA. Analysis was attempted by HRP-coupled AS0 and Southern blotting, and although the results were suboptimal they were interpreted as AS. The state laboratory obtained FA. On the repeat specimen, the microextracted DNA again did not support amplification; no analyses were successful from the repeat circle. Both the original and repeat circles of blood from sample 47 were unacceptable, and in routine practice a repeat sample would have been requested from the patient before any genotypic results could be reported. For sample 2, the state laboratory obtained an FS result, while the DNA laboratory showed AS on all four tests on both the original and the repeat specimen. We suggested to the state laboratory that these results would be consistent with a disorder such as SIP-thalassemia. Additional laboratory testing confirmed this diagnosis for the patient. This discrepancy between the state laboratory and the DNA laboratory was real, and resulted in clinically useful information. After analysis of these 75 specimens, we modified the procedure to use a 1 6-mm2 specimen, representing the dried equivalent of approximately 8 p L whole blood, for direct amplification without microextraction. The automated amplification program was altered by introducing an initial 15-min step at 95°C and increasing the length of the 94°C denaturation step to 1 min. We have had successful direct amplification in 77 of 78 specimens, which were analyzed for the A, S, C, and E alleles using dot-blot hybridization with radiolabeled probe.
Automated direct sequencing after asymmetric PCR was performed successfully on DNA microextracted from newborn screening specimens representing samples with the A, S, and C alleles (Fig. 4) . Heterozygotes were detected by the presence of two different nucleotides at the same position(s) (Fig. 4 , panels AS and SC).
DISCUSSION
Seventy-five newborn screening specimens were evaluated by molecular genetic analysis of the A and S alleles during a 1-mo period. There was complete agreement between the Hb electrophoresis results from the state screening laboratory and the DNA results for 70 of the 75 specimens, or 93% of those analyzed. Results from three (4%) of the specimens that disagreed between the laboratories were attributable to contamination; these three discrepancies were resolved using the remaining semicircle from the original specimen without need for a second sample. The two remaining samples, or 3% of the total group, would have required a repeat blood collection from the patient for clarification. One of these was due to inadequacy of amplification on two attempts from each of two separate circles from the original blotter. The second was due to an actual discrepancy consequent to a genetic compound between the S and a 0-thalassemia allele giving an A result for the second position of the P6 codon targeted by these diagnostic methods. This latter type of discrepancy would provide information of clinical value from the DNA follow-up program. To improve molecular genetic ascertainment of patients with SIP-thalassemia who initially are screened positive (FS) and subsequently are determined to have an AS genotype, we have developed a method using reverse transcriptase followed by PCR amplification for analysis of mRNA from the initial dried blood specimens (3 1).
In the absence of a DNA genotyping program, all positive and equivocal newborn screening test results would be repeated on a second liquid blood specimen drawn at 2-4 mo of age. The cost of contacting the families and acquiring the follow-up specimens are significant expenses that are usually not calculated into the overall cost of a newborn screening program (10) . We have demonstrated that DNA genotyping using the original neonatal screening specimen is feasible and would reduce the number of second specimens required by an estimated 97%. In addition, this would provide more detailed genetic information that would permit better-informed education and counseling of these families at the initial contact, which we have suggested may improve compliance with a~tibiotic prophylaxis and medical management (10) . Based on the results in this study, we have expanded our genotyping capabilities to include not only the A and S alleles but also the C and E alleles using radiolabeled ASO. In addition, it would be possible to expand this diagnostic ability to examine for thalassemias using an ethnicity-based algorithm (28) . Because we can perform at least 30 analyses on each blood specimen using the microextraction or direct amplification procedures, the addition of the thalassemias to the neonatal DNA genotyping repertoire would be feasible.
Automation of the DNA diagnostic procedures will be essential for any large scale neonatal or other population-based screening program, such as is eventually anticipated for CF canier screening (32) . The microextraction procedure, previously described by Jinks et al. (10) and used in the study of the 75 unknown specimens in this report, is extremely personnel intensive and, therefore, would be a costly component of any high-volume DNA diagnostic program based on dried blood spots (33). The procedure described by Schwartz et al. (26) for direct amplification from a small piece cut from a Guthrie card, without microextraction, would decrease dramatically the personnel investment required for specimen processing. This method was based on the demonstration that DNA could be amplified after boiling the dried blood specimens (10) or directly by the thermostable DNA polymerase from Therrnus therrnophilus (26, 34) and was adapted for use with Tag polymerase. This adaptation permits the reduction of sample size from a %-inch diameter semicircle, representing the dried equivalent of approximately 25 pL whole blood, to a 4 X 4 mm square containing approximately 8 pL dried whole blood equivalent. This new procedure of direct amplification without microextraction also eliminates the need for, and disposal of, the toxic material, phenol, resulting in additional cost savings. This adaptation offers an advantage over the earlier boiling procedure (lo), because the filter paper matrix remains in the amplification tube and does not necessitate DNA extraction from the matrix. Therefore, a portion of the DNA may be amplified in situ, as has been reported for crude cell lysates immobilized on nylon membranes (35) .
The cost of DNA genotyping after direct amplification is estimated at $5-10 per sample. This estimate is based on a reagent expense of approximately $2 or less per specimen. A technician would be able to analyze 500-1000 samples per month, resulting in a labor cost of $2-4 per specimen. Therefore, we feel that $5-10 for analysis of a specimen represents a conservative estimate of the cost and compares favorably with protein-based confirmatory testing.
Before direct sample amplification without microextraction, DNA preparation was the rate-limiting step in the procedure. However, the analysis now becomes the limiting factor for sample throughput. We have demonstrated that analysis may be automated using direct automated sequencing by asymmetric PCR. As the cost of automated DNA sequencing is reduced in the course of the human genome initiative, such an approach will become more feasible, especially for examination of regions containing a number of different alleles. A dedicated sequencing apparatus robotically interfaced with equipment for automated amplification would be one potential technologic configuration and would have the advantage of flexibility in the analytical approach (36) . Chehab and Kan (37) have demonstrated that color amplification can differentiate alternative alleles at a specific nucleotide position. This methodology, which is based on competitive oligonucleotide priming (38) , also has the potential for automation. Innovation in the design and implementation of automated DNA analysis will be required for any large volume molecular genetic screening activity.
Dried blood specimens afford the same advantages for DNA analysis that they have demonstrated for over 25 years in neonatal screening: ease of specimen collection and transport to a centralized laboratory and stability of the analyte (1, 2). These attributes have been used not only for genotyping in the hemoglobinopathies (10-14), but also for PKU (6, 7, 26) , CF (8, 9, 18, 19), Duchenne muscular dystrophy (1 5-17), medium-chain acyl CoA dehydrogenase deficiency (20) , and hereditary fructose intolerance (2 1). Experience is showing that these specimens can be used for the same molecular genetic analyses that have been applied to liquid blood specimens.
